MC Sciences is developing the Next Generation Therapeutics targeting mast cells. Based on the discovery of a novel master regulator of the entire mast activity, the novel small molecules are capable of completely inhibiting activated mast cells, thus leading to a disease-modifying effect. By selectively targeting only the activated mast cells and utilizing the by nature designed purpose of the receptor, the safety profile is expected to be superior. These Next Generation therapeutics target a wide range of diseases with high and urgendt unmet need (e.g. chronic urticaria, fibrotics diseases, IDB, neuroinflammation, rare diseases). The discovery of this novel therapeutics is based on a by chance clinical observation and demonstrating high efficacy in humans. The drug development plan is following a promising reverse engineering approach with the major de-risk of high clinical efficacy in humans.
Speaker
